



For Immediate Release

DIMERIX LIMITED ANNUAL GENERAL MEETING NOTICE AND LETTER TO SHAREHOLDERS

MELBOURNE, Australia, 24 August 2021: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company advises the Annual General Meeting of Shareholders of Dimerix Limited (ACN 001 285 230) (**Company**) will be held on Monday, 27 September 2021 at 2:00pm (AEST). The Annual General Meeting will be held as a virtual meeting, accessible online (**Meeting**).

Shareholders will be able to attend and participate in the Meeting via live Zoom audiocast by registering at:

https://us02web.zoom.us/webinar/register/WN_Yhmlb_N4Sk-uj6jtsSTgSg

Given the significant health concerns attributed to the COVID-19 pandemic, in addition to guidelines and restrictions issued by Australian state and federal governments, the Company considers that it is appropriate to hold the Annual General Meeting as a virtual meeting accessible online, in a manner that is consistent with ASIC's "no action" position (adopted on 29 March 2021) and the temporary relief measures introduced by the federal government in Treasury Laws Amendment (2021 Measures No. 1) Act 2021 (Cth) (Relief Measures).

Additionally, in accordance with the Relief Measures in relation to electronic notice of meetings, the Notice is being made available to Shareholders electronically and can be viewed and downloaded online at the following link: www.dimerix.com

Further instructions are set out in the Notice and accompanying letter to shareholders which is attached to this release.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster, Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Authorised for lodgement by the Board of the Company

—END—

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com



Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix Limited to be materially different from the statements in this announcement.

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product, DMX-200, for Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) and Acute Respiratory Distress Syndrome (ARDS), and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032.

In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all study endpoints were achieved. The compelling results from this study prompted the decision to initiate two different clinical studies in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS). DMX-200 is also under investigation as a potential treatment for acute respiratory distress syndrome (ARDS) in patients with COVID-19.

FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old. For those who are fortunate enough to receive a kidney transplant, approximately 40% will get re-occurring FSGS in the transplanted kidney. At this time, there are no drugs approved for FSGS anywhere in the world, so the treatment options and prognosis are poor.

FSGS is a billion-dollar plus market: the number of people with FSGS in the US alone is just over 80,000, and worldwide about 210,000. The illness has a global compound annual growth rate of 8%, with over 5,400 new cases diagnosed in the US alone each year. Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX-200 in both the US and Europe for FSGS. This is a special status granted to a drug to treat a rare disease or condition; the designation means that DMX-200 can potentially be fast-tracked, and receive tax and other concessions to help it get to market.

DMX-200 for FSGS has been granted Orphan Drug Designation by the FDA and EMA. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com



incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and an abbreviated regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

24 August 2021

ANNUAL GENERAL MEETING – NOTICE AND PROXY FORM

Dear Shareholder

Notice is hereby given that the Annual General Meeting of Shareholders of Dimerix Limited (ACN 001 285 230) (**Company**) will be held on Monday, 27 September 2021 at 2:00pm (AEST). The Annual General Meeting will be held as a virtual meeting, accessible online (**Meeting**).

Given the significant health concerns attributed to the COVID-19 pandemic, in addition to guidelines and restrictions issued by Australian state and federal governments, the Company considers that it is appropriate to hold the Annual General Meeting as a virtual meeting accessible online, in a manner that is consistent with ASIC's "no action" position (adopted on 29 March 2021) and the temporary relief measures introduced by the federal government in *Treasury Laws Amendment (2021 Measures No. 1) Act 2021* (Cth) (**Relief Measures**).

Shareholders will be able to attend and participate in the Meeting via live Zoom audiocast by registering at:

https://us02web.zoom.us/webinar/register/WN_Yhmlb_N4Sk-uj6jtsSTgSg

Further instructions are set out in the Notice of Meeting (**Notice**).

Shareholders will be able to vote and ask questions at the virtual meeting. Shareholders are also encouraged to submit questions in advance of the Meeting of the Company. Questions must be submitted in writing to Hamish George, the Company Secretary at accounts@dimerix.com at least 48 hours before the Meeting.

Additionally, in accordance with the Relief Measures in relation to electronic notice of meetings, the Notice is being made available to Shareholders electronically and can be viewed and downloaded online at the following link: www.dimerix.com

If you have not elected to receive notices by email, you will receive this letter by mail with a copy of your personalised proxy form enclosed for your convenience.

Voting by Proxy

To vote by proxy:

1. Please lodge the Proxy Form online at <https://investor.automic.com.au/#/loginsh> by following the instructions:
 - i. Login to the Automic website using the holding details as shown on the Proxy Form.
 - ii. Click on 'View Meetings' – 'Vote'.

To use the online lodgement facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown on the front of the Proxy Form.

2. Please complete and sign your attached Proxy Form, and deliver it to the Company's share registry, Automic Group:
 - i. by post to: Automic, GPO Box 5193, Sydney NSW 2001; or
 - ii. by email to: meetings@automicgroup.com.au.

Your proxy voting instruction must be received by 2:00pm (AEST) on 25 September 2021, being not less than 48 hours before the commencement of the Meeting. **Any proxy voting instructions received after that time will not be valid for the Meeting.**

The Notice is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial adviser, lawyer, accountant or other professional adviser. If you have any difficulties obtaining a copy of the Notice please contact the Company's share registry, Automic Group on, 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Yours sincerely,



Dr James Williams
Non-Executive Chairman